Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taste Profile of Rilematovir Oral Liquid Formulations
NCT02426632Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rilematovir in respiratory syncytial virus infection (RSV) (12 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Acceptability Score. Started Mar 2015; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02426632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426632.